Phase I study of S-222611 in patients with advanced EGFR- and/or HER2-expressing solid tumours

Trial Profile

Phase I study of S-222611 in patients with advanced EGFR- and/or HER2-expressing solid tumours

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Dec 2015

At a glance

  • Drugs S 222611 (Primary)
  • Indications Advanced breast cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Pancreatic cancer; Renal cancer; Solid tumours
  • Focus Adverse reactions; Pharmacokinetics
  • Most Recent Events

    • 12 Dec 2015 Results (n=76) presented at the 38th Annual San Antonio Breast Cancer Symposium.
    • 29 Oct 2015 Status changed from active, no longer recruiting to completed as results of both escalation and expansion phase are published.
    • 02 Jun 2015 Results (Expansion; n=76) presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top